Mochida Pharmaceutical Co., Ltd.

Yoshitaka Hosaka

Shoji Furusako

Tetsushi Kawahara

Katsuki Naitoh

Motoyasu Honda

Kamon Shirakawa

Tomokazu Matsusue

Yumi Hotta

Hiroshi Takayama

Takashi Takeuchi

Masaki Nakamura

Kazuyuki Nakayama

A protein comprising (I) an anti-CDantibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Polynucleotide encoding anti-CD14 antibody fusion protein

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Anti-platelet membrane glycoprotein VI monoclonal antibody

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:

The present invention provides a convenient and highly sensitive method of determining sGPVI present in plasma; this is accomplished by establishing a plurality of mouse hybridomas that produce antibody against GPVI and combining the antibodies produced therefrom. Provided thereby are a novel platelet activation marker, a reagent and method for determining this novel platelet activation marker, and novel applications of this marker in, for example, the diagnosis of diseases associated with platelet activation/vascular endothelial injury.

Methods of detection GPVI

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Growing community of inventors

Tokyo, Japan

Yoshitaka Hosaka